Kai Rejeski

3.4k total citations · 2 hit papers
64 papers, 947 citations indexed

About

Kai Rejeski is a scholar working on Oncology, Electrical and Electronic Engineering and Immunology. According to data from OpenAlex, Kai Rejeski has authored 64 papers receiving a total of 947 indexed citations (citations by other indexed papers that have themselves been cited), including 54 papers in Oncology, 13 papers in Electrical and Electronic Engineering and 11 papers in Immunology. Recurrent topics in Kai Rejeski's work include CAR-T cell therapy research (53 papers), Integrated Circuits and Semiconductor Failure Analysis (12 papers) and Lymphoma Diagnosis and Treatment (9 papers). Kai Rejeski is often cited by papers focused on CAR-T cell therapy research (53 papers), Integrated Circuits and Semiconductor Failure Analysis (12 papers) and Lymphoma Diagnosis and Treatment (9 papers). Kai Rejeski collaborates with scholars based in Germany, United States and France. Kai Rejeski's co-authors include Marion Subklewe, Michael D. Jain, Michael von Bergwelt‐Baildon, David M. Cordas dos Santos, Miguel‐Angel Perales, Veit Bücklein, Viktoria Blumenberg, Frederick L. Locke, Roni Shouval and Sebastian Theurich and has published in prestigious journals such as Nature Medicine, Blood and Oncogene.

In The Last Decade

Kai Rejeski

58 papers receiving 944 citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

A systematic review and meta-analysis of nonrelapse mortality after CAR T cell therapy

2024 99 citations David M. Cordas dos Santos, Roni Shouval et al. Nature Medicine profile →
Second Primary Malignancies after CAR T-Cell Therapy: A Systematic Review and Meta-analysis of 5,517 Lymphoma and Myeloma Patients

2024 44 citations Roni Shouval, Edward R. Scheffer Cliff et al. profile →

Peers

Countries citing papers authored by Kai Rejeski

Since Specialization

Citations

This map shows the geographic impact of Kai Rejeski's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Kai Rejeski with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Kai Rejeski more than expected).

Fields of papers citing papers by Kai Rejeski

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Kai Rejeski. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Kai Rejeski. The network helps show where Kai Rejeski may publish in the future.

Co-authorship network of co-authors of Kai Rejeski

This figure shows the co-authorship network connecting the top 25 collaborators of Kai Rejeski. A scholar is included among the top collaborators of Kai Rejeski based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Kai Rejeski. Kai Rejeski is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Immunoglobulin prophylaxis should be initiated after bispecific antibody therapy in multiple myeloma, regardless of IgG levels 2025 ·Blood Advances ·Rahul Banerjee, Meera Mohan, Kai Rejeski, (unknown), Diana Cirstea, Gurbakhash Kaur, Shonali Midha, Georgia McCaughan, (unknown), Nikita Mehra, Bhausaheb Bagal, Noopur Raje	2
2	Pre-infusion risk factors predict severe infectious complications of CAR T-cell therapy in pediatric and adult patients with B-ALL 2025 ·Journal for ImmunoTherapy of Cancer ·(unknown), (unknown), Yannis K. Valtis, (unknown), Surabhi B Vora, Joseph M. Rocco, Véronique Nussenblatt, Sara Silbert, Haneen Shalabi, Bonnie Yates, Jae H. Park, Adam J. Lamble, Kai Rejeski, Nirali N. Shah	0
3	Prognostic significance of immune reconstitution following CD19 CAR T‐cell therapy for relapsed/refractory B‐cell lymphoma 2025 ·HemaSphere ·Sophia Stock, Veit Bücklein, Viktoria Blumenberg, (unknown), (unknown), Alessandra Holzem, David M. Cordas dos Santos, (unknown), (unknown), Lisa Frölich, Sebastian Kobold, Michael von Bergwelt‐Baildon, Kai Rejeski, (unknown)	6
4	Noncanonical and mortality-defining toxicities of CAR T cell therapy 2025 ·Nature Medicine ·Kai Rejeski, Joshua A. Hill, Saurabh Dahiya, Michael D. Jain	1
5	Safety and efficacy of bridging radiation therapy prior to CD19 CAR T for non-Hodgkin lymphoma: a systematic review and meta-analysis 2025 ·Haematologica ·(unknown), (unknown), Michelle Demetres, Kai Rejeski, Michael Scordo, Roni Shouval, (unknown), J. Martinet, (unknown), (unknown), Tsiporah B. Shore, Paul G. Pagnini, Mahmoud Aljurf, (unknown), Silvia C. Formenti, Joachim Yahalom, (unknown), Brandon S. Imber, Zhengming Chen, (unknown)	0
6	Comparative performance of scFv-based anti-BCMA CAR formats for improved T cell therapy in multiple myeloma 2024 ·Cancer Immunology Immunotherapy ·Sophia Stock, (unknown), Adrian Gottschlich, Janina Dörr, Florian Märkl, (unknown), (unknown), Ruth Grünmeier, Kai Rejeski, David M. Cordas dos Santos, Sebastian Theurich, Michael von Bergwelt‐Baildon, Stefan Endres, Marion Subklewe, Sebastian Kobold	2
7	Cohort Comparison of Therapy-Related Myeloid Neoplasms after CAR T-Cell Therapy, Autologous Stem Cell Transplant, and Standard Cancer Therapies 2024 ·Blood ·Juan Manuel Mancilla Díaz, Saurabh Dahiya, (unknown), Maeve O’Reilly, Kai Rejeski, Veit Buecklein, Marion Subklewe, Gloria Iacoboni, Pere Barba, Claire Roddie, Frederick L. Locke, Jay Y. Spiegel, Najla H. Al Ali, (unknown), Jongphil Kim, Rami S. Komrokji, Michael D. Jain	0
8	Applying the EHA/EBMT grading for ICAHT after CAR-T: comparative incidence and association with infections and mortality 2024 ·Blood Advances ·Kai Rejeski, Yucai Wang, Doris K. Hansen, Gloria Iacoboni, Emmanuel Bachy, Radhika Bansal, Olaf Penack, Fabian Müller, Wolfgang Bethge, Javier Muñoz, Razan Mohty, Veit Bücklein, Pere Barba, Frederick L. Locke, (unknown), Michael D. Jain, Marion Subklewe	29
9	A systematic review and meta-analysis of nonrelapse mortality after CAR T cell therapy breakdown → 2024 ·Nature Medicine ·David M. Cordas dos Santos, (unknown), Roni Shouval, Anat Gafter‐Gvili, (unknown), Edward R. Scheffer Cliff, Sebastian Theurich, Michael von Bergwelt‐Baildon, Irene M. Ghobrial, (unknown), Miguel‐Angel Perales, Kai Rejeski	99
10	Development and validation of an automated computational approach to grade immune effector cell-associated hematotoxicity 2024 ·Bone Marrow Transplantation ·Emily C. Liang, Kai Rejeski, Teng Fei, (unknown), Jennifer J. Huang, Andrew J. Portuguese, Qian Wu, Sandeep Raj, Marion Subklewe, Roni Shouval, Jordan Gauthier	6
11	Secondary Hematologic Malignancies in Patients Following Chimeric Antigen Receptor T-Cell Therapy: Aggregated Clinical Trial Data from 1542 Patients 2024 ·Blood ·Edward R. Scheffer Cliff, (unknown), (unknown), Jacob W. Aptekar, David A. Russler‐Germain, Kai Rejeski, Aaron S. Kesselheim	1
12	Applying the Novel EHA/EBMT Grading System for Icaht Following CAR-T Therapy: Comparative Incidence across Disease Entities and Association with Infections and Mortality 2023 ·Blood ·Kai Rejeski, Doris K. Hansen, Yucai Wang, Gloria Iacoboni, Emmanuel Bachy, Radhika Bansal, Olaf Penack, (unknown), Wolfgang Bethge, Javier Muñoz, Razan Mohty, Veit Buecklein, Pere Barba, Frederick L. Locke, Yi Lin, Michael D. Jain, Marion Subklewe	1
13	The CAR‐HEMATOTOX score identifies patients at high risk for hematological toxicity, infectious complications, and poor treatment outcomes following brexucabtagene autoleucel for relapsed or refractory MCL 2023 ·American Journal of Hematology ·Kai Rejeski, Yucai Wang, Omar Albanyan, Javier Muñoz, Pierre Sesques, Gloria Iacoboni, Lucía López‐Corral, (unknown), Veit Bücklein, Razan Mohty, Martin Dreyling, Aliyah Baluch, Bijal Shah, Frederick L. Locke, Georg Heß, Pere Barba, Emmanuel Bachy, Yi Lin, Marion Subklewe, Michael D. Jain	17
14	Influence of Adipose Tissue Distribution, Sarcopenia, and Nutritional Status on Clinical Outcomes After CD19 CAR T-cell Therapy 2023 ·Cancer Immunology Research ·Kai Rejeski, David M. Cordas dos Santos, Nathan H. Parker, Veit Bücklein, Michael Winkelmann, (unknown), (unknown), (unknown), Sophie Günther, Philipp Karschnia, Viktoria Blumenberg, (unknown), Wolfgang G. Kunz, Michael von Bergwelt‐Baildon, Michael D. Jain, Sebastian Theurich, Marion Subklewe	20
15	Infections after chimeric antigen receptor (CAR)‐T‐cell therapy for hematologic malignancies 2023 ·Transplant Infectious Disease ·Eleftheria Kampouri, Jessica S Little, Kai Rejeski, Oriol Manuel, Sarah P. Hammond, Joshua A. Hill	55
16	Recognizing, defining, and managing CAR-T hematologic toxicities 2023 ·Hematology ·Kai Rejeski, Marion Subklewe, Frederick L. Locke	24
17	Modification of Lugano criteria by pre-infusion tumor kinetics improves early survival prediction for patients with lymphoma under chimeric antigen receptor T-cell therapy 2023 ·Journal for ImmunoTherapy of Cancer ·Michael Winkelmann, Viktoria Blumenberg, Kai Rejeski, (unknown), Veit Bücklein, (unknown), Marcus Unterrainer, Christian Schmidt, (unknown), Peter Bartenstein, Jens Ricke, Michael von Bergwelt‐Baildon, Marion Subklewe, Wolfgang G. Kunz	0
18	Shunt dependency in supratentorial intraventricular tumors depends on the extent of tumor resection 2023 ·Acta Neurochirurgica ·Nico Teske, (unknown), (unknown), Patrick N. Harter, Kai Rejeski, (unknown), Louisa von Baumgarten, Joerg‐Christian Tonn, Mathias Kunz, Niklas Thon, Philipp Karschnia	6
19	Real-World Evidence of Brexucabtagene Autoleucel for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma 2021 ·Blood ·Gloria Iacoboni, Kai Rejeski, (unknown), Annalisa Chiappella, (unknown), Lucía López‐Corral, Mariana Bastos‐Oreiro, (unknown), Christian Schmidt, Cecilia Carpio, Juan Luís Reguera, Mi Kwon, Alejandro Martı́n, Pier Luigi Zinzani, Paolo Corradini, Marion Subklewe, Pere Barba	7
20	Subventricular zone involvement is associated with worse outcome in glioma WHO grade 2 depending on molecular markers 2021 ·Scientific Reports ·Philipp Karschnia, Jonathan Weller, (unknown), Veit M. Stoecklein, Mario M. Dorostkar, Kai Rejeski, Robert Forbrig, Maximilian Niyazi, Louisa von Baumgarten, Jörg Dietrich, Joerg‐Christian Tonn, Niklas Thon	2

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact